🎁 Black Friday: 50% off Unlimited and 30% off Pro annual plans
Reviva Pharmaceuticals Holdings, Inc. (RVPH)
OTCMKTS · Delayed Price · Currency is USD
0.3000
-0.0550 (-15.49%)
At close: Nov 18, 2026

RVPH Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Selling, General & Admin
6.118.497.898.085.365.25
Research & Development
5.7711.7122.9131.4222.874.85
Operating Expenses
11.8820.230.839.528.2310.1
Operating Income
-11.88-20.2-30.8-39.5-28.23-10.1
Interest Expense
-0.01-0.01-0.02-0.03--0
Interest & Investment Income
0.540.310.360.40.18-
Other Non Operating Income (Expenses)
0.040.060.56-0.1-0.191.59
Pretax Income
-11.3-19.85-29.9-39.24-28.24-8.52
Income Tax Expense
0.010.020.020.020.020.01
Net Income
-11.31-19.86-29.92-39.26-28.26-8.52
Net Income to Common
-11.31-19.86-29.92-39.26-28.26-8.52
Net Income Growth
------
Shares Outstanding (Basic)
1042111
Shares Outstanding (Diluted)
1042111
Shares Change
275.26%114.96%41.84%21.94%31.95%383.10%
EPS (Basic)
-1.15-5.48-17.73-32.99-28.96-11.52
EPS (Diluted)
-1.15-5.48-17.73-32.99-28.96-11.52
EPS Growth
------

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
EBITDA
------10.1
D&A For EBITDA
-----0
EBIT
-11.88-20.2-30.8-39.5-28.23-10.1